pH-Dependent Solid Dispersion for Low-Solubility Tankyrase Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The triazolopyrimidinone derivative of Chemical Formula I, a crystalline material with high permeability and very low solubility, requires a novel formulation to enhance its solubility and bioavailability for effective therapeutic use in treating various diseases, including cancer and hyperproliferative conditions.
Innovation Solution
A solid dispersion comprising a compound represented by Chemical Formula I and a pH-dependent polymer, such as hydroxypropyl methylcellulose acetate succinate (HPMCAS), is developed, which significantly improves solubility and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the triazolopyrimidinone derivative is used as a crystalline material, then high permeability is achieved, but solubility is very low
Solution Approach 1:
The patent transforms the crystalline compound from BCS class II (high permeability, low solubility) to an amorphous solid dispersion, fundamentally changing the physical state and dissolution behavior. This parameter change enables the compound to exhibit both high apparent solubility and maintained permeability characteristics
Solution Approach 2:
The patent creates a composite system by dispersing the triazolopyrimidinone derivative within a polymer matrix (such as HPMCAS or Eudragit). This composite approach combines the permeability benefits of the original compound with the solubility-enhancing properties of the amorphous polymer matrix, achieving both high permeability and improved solubility simultaneously
2Reliability
If the compound is formulated to improve solubility, then bioavailability is enhanced, but formulation complexity increases
Solution Approach 1:
By changing the physical state from crystalline to amorphous and utilizing pH-dependent polymer matrices, the formulation achieves enhanced bioavailability through improved dissolution. The pH-dependent release mechanism provides controlled drug delivery without requiring complex multi-component formulations
Solution Approach 2:
The patent introduces pH-dependent polymers as intermediaries that mediate between the poorly soluble compound and the gastrointestinal environment. These polymers provide a simple yet effective mechanism for enhancing bioavailability through pH-triggered dissolution and release, avoiding the need for complex formulation systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solid dispersion exhibits high solubility and excellent bioavailability, making it suitable for use as a pharmaceutical raw material, with solubility improvements up to approximately 10 times higher than the compound alone and bioavailability enhancements of up to approximately 7 times.
Implementation Method 1
The pH-dependent polymer may be, for example, a polymer material having a functional group whose charge state varies depending on pH conditions
Data Source
AI summary
The present invention relates to a solid dispersion of a triazolopyrimidinone derivative exhibiting tankyrase inhibitory activity, and a method for preparing the same. The solid dispersion of the triazolopyrimidinone derivative represented by Chemical Formula I according to the present invention has high solubility and excellent bioavailability, and thus can be usefully employed as a pharmaceutical raw material.